RecallRadar

FDA Drug recall D-0105-2025

Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ…

On 2024-12-11 the FDA classified a Class II recall of Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ… by Rising Pharma Holding, citing CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0105-2025
ClassificationClass II
Statusongoing
Initiated2024-11-19
Published2024-12-11
Last updated2026-09-13 11:52 UTC
CompanyRising Pharma Holding
DistributionUS

Product

Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60

Reason

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Identifiers

code_infoa) Lot # DT2022023A, DT2022024A, DT2022025A, DT2022026A, DT2022027A, exp. date Nov-24 DT2023001B, DT2023004A, DT2023005A, DT2023006A, exp. date Jan-25

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0105-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.